Study of First line mantle cell lymphoma treatment by Rituximab, Velcade, Bendamustine and
Dexamethasone schema in patients older than 65 years or 18 to 65 years old who cannot or
refuse receive conditioning regimen followed by autograft.
Phase:
Phase 2
Details
Lead Sponsor:
French Innovative Leukemia Organisation
Collaborators:
Chugai Pharma Europe Ltd. Janssen-Cilag Ltd. Lymphoma Study Association Mundipharma Pte Ltd. Roche Pharma AG